Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ORGANIZATION
ORGANIZATION
- JPMA Reinstates MSD K.K. as Member After 22-Month Suspension
April 22, 2013
- Tug-of-War over “Conflicts of Interest” (1): Drug Makers, Doctors Remain Divided
April 18, 2013
- APAC to Draft Roadmap for Early Drug Application and Approval in Asia
April 16, 2013
- JPMA Eyes Joint Communications Campaigns for Transparency Guidelines with JMA, JAMS
April 12, 2013
- Pharma Officials Puzzled at Fuzzy Communications Provision in JPMA Code of Practice
April 1, 2013
- Keizai Doyukai Urges Government to Switch All Long-Listed Products to Generics to Cut Social Security Costs
March 29, 2013
- Survey by Japan Hospital Association Finds Big Increase in Accounts Receivable per Hospital in 2012
March 27, 2013
- FPMAJ to Set Up International Affairs Committee and Self-Medication Task Force
March 25, 2013
- JPMA Suspends Activities of Vice President Hasegawa for Six Months and Membership of Nihon Pharmaceutical
March 22, 2013
- JPMA Officially Decides on One-Year Postponement of Individual Payment Disclosures under Transparency Guidelines
March 22, 2013
- JPWA Vice President Ken Suzuki Expected to Lead JPWA After President Bessho’s Term Ends in May
March 22, 2013
- EFPIA Simulation: New Drug Market Up Mere 0.4 Trillion Yen by 2022 Even with Premium
March 19, 2013
- Transparency Guidelines: JPMA Proposes One-Year Hold on Disclosure of Individual Payments
March 18, 2013
- Japan Society of Generic Medicines Calls for 80% Generic Drug Share by Volume within 5 Years
March 8, 2013
- JPMA Issues Statement Calling for IP Protection, Expresses Concerns over Issuance of Compulsory Licenses
March 7, 2013
- Generic Market Share at 26.1% on Volume Basis in 3rd Quarter FY2012: JGA
March 6, 2013
- Relationships with Doctors Unchanged after Stricter Rules on Entertainment: Maker FTC Survey
February 27, 2013
- Yakukeiren’s Direct Joint Purchasing System for Generic Drugs to Go into Full Operation in FY2013
February 27, 2013
- TPP Hoped to Set Standard for Global IP Protection Rules: PhRMA Japan Rep. Wolf
February 25, 2013
- JPMA’s Nakatani Says Transparency Guidelines Will Go into Force in April as Planned
February 25, 2013
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…